Clair Health, a San Francisco startup founded by two Stanford graduates, raises about $11–$11.6 million in seed funding to develop a noninvasive wearable for continuous hormone tracking. Multiple outlets report the company’s goal is to monitor hormone levels without blood draws, positioning the device as a continuous alternative for women’s hormone measurement. The funding round is led by Khosla Ventures, with participation from firms and investors including a16z speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and 23andMe co-founder Anne Wojcicki. The company’s planned product includes a wearable device and a companion app. One outlet reports a target retail price of $369 for the device, along with an app-based subscription priced at $9.99 per month. Clair Health describes its approach as enabling continuous tracking through noninvasive sensing, though specific technical details and clinical validation are not included in the provided excerpts. The reported investment and pricing suggest the company intends to commercialize the device through a hardware-plus-subscription model.